The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Open accessAbstract
Preclinical models have shown that blocking PD-1/PD-L1 pathways enhances antileukemic responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this single-arm trial, in which patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) were treated with azacitidine 75 mg/m2 days 1 to 7 intravenously or subcutaneously with nivolumab 3 mg/kg intravenously on days 1 and 14, every 4 to 6 weeks. For the seventy patients who were treated, the median age was 70 years (range, 22–90) and the median number of prior therapies received was 2 (range, 1–7). The overall response rate (ORR) was 33%, including 15 (22%) complete remission/complete remission with insufficient recovery of counts, 1 partial response, and 7 patients with hematologic improvement maintained >6 months. Six patients (9%) had stable disease >6 months. The ORR was 58% and 22%, in hypomethylating agent (HMA)–naïve (n = 25) and HMA-pretreated (n = 45) patients, respectively. Grade 3 to 4 immune-related adverse events occurred in 8 (11%) patients. Pretherapy bone marrow and peripheral blood CD3 and CD8 were significantly predictive for response on flow cytometry. CTLA4 was significantly upregulated on CD4+ Teff in nonresponders after 2 and 4 doses of nivolumab. Azacitidine and nivolumab therapy produced an encouraging response rate and overall survival in patients with R/R AML, particularly in HMA-naïve and salvage 1 patients. Pretherapy bone marrow aspirate and peripheral blood CD3 percentage may be biomarkers for patient selection. Significance: Azacitidine in combination with nivolumab appeared to be a safe and effective therapy in patients with AML who were salvage 1, prior hypomethylator-naïve, or had increased pretherapy CD3+ bone marrow infiltrate by flow cytometry or IHC. Bone marrow CD3 and CD8 are relatively simple assays that should be incorporated to select patients in future trials. This article is highlighted in the In This Issue feature, p. 305
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,413
Self-citationTopp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Self-citationFenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
DiNardo, C. D., Pratz, K. W., Letai, A., Jonas, B. A., Wei, A. H., Thirman, M., Arellano, M., Frattini, M. G., Kantarjian, H., Popovic, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30010-x · Cited by 722
Self-citationYang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688
Self-citationBerger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Davids, M. S., Kim, H. T., Bachireddy, P., Costello, C., Liguori, R., Savell, A., Lukez, A. P., Avigan, D., Chen, Y.-B., McSweeney, P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601202 · Cited by 593
Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70551-5 · Cited by 529
DiNardo, C. D., Rausch, C. R., Benton, C., Kadia, T., Jain, N., Pemmaraju, N., Daver, N., Covert, W., Marx, K. R., Mace, M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25000 · Cited by 424
Self-citationPD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Zhang, L., Gajewski, T. F., & Kline, J. (2009) · Blood · doi:10.1182/blood-2009-03-206672 · Cited by 411
Alterations of immune response of non-small cell lung cancer with Azacytidine
Wrangle, J., Wang, W., Koch, A., Easwaran, H., Mohammad, H. P., Pan, X., Vendetti, F., VanCriekinge, W., DeMeyer, T., Du, Z., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1542 · Cited by 386
Tang, C., Welsh, J. W., de Groot, P., Massarelli, E., Chang, J. Y., Hess, K. R., Basu, S., Curran, M. A., Cabanillas, M. E., Subbiah, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1432 · Cited by 321
Self-citationStromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer
Donnem, T., Hald, S. M., Paulsen, E.-E., Richardsen, E., Al-Saad, S., Kilvaer, T. K., Brustugun, O. T., Helland, A., Lund-Iversen, M., Poehl, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1905 · Cited by 312
Zhou, Q., Munger, M. E., Highfill, S. L., Tolar, J., Weigel, B. J., Riddle, M., Sharpe, A. H., Vallera, D. A., Azuma, M., Levine, B. L., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275446 · Cited by 287
Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes
Thol, F., Friesen, I., Damm, F., Yun, H., Weissinger, E. M., Krauter, J., Wagner, K., Chaturvedi, A., Sharma, A., Wichmann, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4938 · Cited by 277
Le Dieu, R., Taussig, D. C., Ramsay, A. G., Mitter, R., Miraki-Moud, F., Fatah, R., Lee, A. M., Lister, T. A., & Gribben, J. G. (2009) · Blood · doi:10.1182/blood-2009-02-206946 · Cited by 243
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, A., Hyjek, E., Ma, N., Lesokhin, A., Dogan, A., Rapoport, A. P., Kocoglu, M., Lederer, E., Philip, S., Milliron, T., et al. (2017) · Blood · doi:10.1182/blood-2017-03-775122 · Cited by 197 · cited 1×
“These are well-established biomarkers of response to ICPIs in other tumor types (27, 28).”
BackgroundLuthra, R., Patel, K. P., Reddy, N. G., Haghshenas, V., Routbort, M. J., Harmon, M. A., Barkoh, B. A., Kanagal-Shamanna, R., Ravandi, F., Cortes, J. E., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.093765 · Cited by 180
Self-citationDaver, N., Boddu, P., Garcia-Manero, G., Yadav, S. S., Sharma, P., Allison, J., & Kantarjian, H. (2018) · Leukemia · doi:10.1038/s41375-018-0070-8 · Cited by 179
Self-citationStahl, M. F., DeVeaux, M., Montesinos, P., Itzykson, R., Ritchie, E. K., Sekeres, M. A., Barnard, J., Podoltsev, N. A., Brunner, A. M., Komrokji, R. S., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016121 · Cited by 146
Thall, P. F., & Sung, H. (1998) · Statistics in Medicine · Cited by 121
Th17 cells and interleukin‐17 increase with poor prognosis in patients with acute myeloid leukemia
Han, Y., Ye, A., Bi, L., Wu, J., Kang, Y., & Zhang, S. (2014) · Cancer Science · doi:10.1111/cas.12459 · Cited by 106
Wu, C., Wang, S., Wang, F., Chen, Q., Peng, S., Zhang, Y., Qian, J., Jin, J., & Xu, H. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.04011.x · Cited by 99
Tawfik, B., Sliesoraitis, S., Lyerly, S., Klepin, H. D., Lawrence, J. A., Isom, S. P., Ellis, L. R., Manuel, M., Dralle, S., Berenzon, D. P., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1940-9 · Cited by 59
Goldberg, A. D., Horvat, T. Z., Hsu, M., Devlin, S. M., Cuello, B. M., Daley, R. J., King, A. C., Buie, L. W., Glass, J. L., Mauro, M. J., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.1353.1353 · Cited by 23
Cited by
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion
Su, R., Dong, L., Li, Y., Gao, M., Han, L., Wunderlich, M., Deng, X., Li, H., Huang, Y., Gao, L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.017 · Cited by 763
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 561
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Short, N. J., Konopleva, M., Kadia, T. M., Borthakur, G., Ravandi, F., DiNardo, C. D., & Daver, N. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1011 · Cited by 368
Self-citation
Metadata
- Authors
- Daver, N., Garcia-Manero, G., Basu, S., Boddu, P. C., Alfayez, M., Cortes, J. E., Konopleva, M., Ravandi-Kashani, F., Jabbour, E., Kadia, T., Nogueras-Gonzalez, G. M., Ning, J., Pemmaraju, N., DiNardo, C. D., Andreeff, M., Pierce, S. A., Gordon, T., Kornblau, S. M., Flores, W., Alhamal, Z., Bueso-Ramos, C., Jorgensen, J. L., Patel, K. P., Blando, J., Allison, J. P., Sharma, P., & Kantarjian, H.
- Venue
- Cancer Discovery
- Published
- 2019-03-01
- Volume
- 9
- Issue
- 3
- Pages
- 370-383
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2900410545
- Cited by
- 555
- References
- 33
- FWCI
- 32.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.